An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Genprex, a clinical-stage gene therapy company (NASDAQ: GNPX), announced its participation in key investor and healthcare conferences in January 2022. CEO Rodney Varner and CMO Mark Berger will lead presentations at events including the HC Wainwright BIOCONNECT, Biotech Showcase, and the Precision Lung Cancer World R&D Summit. The CEO Roadshow presentation is scheduled for January 26, 2022. Genprex focuses on developing gene therapies for cancer and diabetes, utilizing their proprietary ONCOPREX® delivery system. REQORSA™, their lead candidate for lung cancer, has received Fast Track Designation from the FDA.
Positive
None.
Negative
None.
HC Wainwright BIOCONNECT 2022 Virtual Conference - January 10-13
Biotech Showcase 2022 - January 10-13
Precision: Lung Cancer World R&D Virtual Summit - January 25-26
CEO Roadshow - January 26
AUSTIN, Texas--(BUSINESS WIRE)--
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its participation in upcoming investor and healthcare conferences to be held in January 2022. Genprex’s President and Chief Executive Officer, Rodney Varner, and the Company’s Chief Medical Officer, Mark Berger, MD will lead the Company’s presentations.
Details on Genprex’s participation in January conferences include:
Event: HC Wainwright BIOCONNECT 2022 Virtual Conference Conference Dates:January 10-13, 2022 Presentation Time: Available on-demand beginning January 10 at 7 a.m. EST Presenters:Rodney Varner, President and Chief Executive Officer and Mark Berger, MD, Chief Medical Officer
Conference Registration: https://bit.ly/3lMBq6G
Webcast Link:https://bit.ly/3q5EewX
Event: Biotech Showcase 2022
Conference Dates:January 10-13, 2022 Presentation Time: Available on-demand beginning January 10 Presenter:Rodney Varner, President and Chief Executive Officer
Conference Registration: https://bit.ly/3y80EB5
Event: Precision: Lung Cancer World R&D Virtual Summit
Conference Dates:January 25-26 Presentation Date: Tuesday,January 25 Presenters:Mark Berger, MD, Chief Medical Officer
Conference Registration: https://bit.ly/3pxW1wg
Event: CEO Roadshow
Presentation Date: Wednesday,January 26 Presentation Time: 11 a.m. EST Presenters:Rodney Varner, President and Chief Executive Officer
Location: Virtual Webinar
Conference Registration: https://bit.ly/3IxMrSY
At these virtual events, Mr. Varner and Dr. Berger will either be available to participate in virtual one-on-one meetings with registered participants or will be available for questions following the Company presentation. If available, a recording of these presentations will be available for replay on Genprex’s website for a period of time.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA for NSCLC in combination therapy with Merck & Co’s Keytruda® (pembrolizumab) for patients whose disease progressed after treatment with Keytruda.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K and “Part II, Item 1A” of Genprex’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals, including the extent and impact of the COVID-19 pandemic; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
What conferences is Genprex (GNPX) attending in January 2022?
Genprex (GNPX) will participate in the HC Wainwright BIOCONNECT, Biotech Showcase, Precision Lung Cancer World R&D Summit, and a CEO Roadshow all scheduled for January 2022.
Who will present for Genprex (GNPX) at the conferences?
Rodney Varner, CEO, and Mark Berger, CMO, will present at the upcoming conferences for Genprex (GNPX).
When is the CEO Roadshow presentation for Genprex (GNPX)?
The CEO Roadshow presentation for Genprex (GNPX) is set for January 26, 2022, at 11 a.m. EST.
What is REQORSA™ and its significance for Genprex (GNPX)?
REQORSA™ is Genprex's lead gene therapy candidate for non-small cell lung cancer (NSCLC) and has received Fast Track Designation from the FDA for use in combination therapies.
What is the ONCOPREX® system used by Genprex (GNPX)?
The ONCOPREX® system is a proprietary non-viral nanoparticle delivery platform designed to administer gene therapies specifically for cancer treatment.
